百奥泰：与AvalonPharma签署协议许可BAT3306注射液商业化权益

Core Viewpoint - The company has signed a licensing, production, supply, and commercialization agreement with Avalon Pharma for the exclusive commercialization rights of BAT3306 (Pablocizumab) injection in Saudi Arabia and the MENA region, which is expected to positively impact future performance and enhance profitability [1] Group 1 - The agreement includes an upfront payment of $2 million [1] - The total milestone payments will not exceed $5 million [1] - The revenue sharing will involve a double-digit percentage of net sales [1] Group 2 - The agreement is effective for fifteen years, with an option to extend for an additional two years [1]